FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with Beta-Thalassemia who Require Regular Red Blood Cell Transfusions

bluebird bio, Inc. announced the outcome of the FDA Cellular, Tissue, and Gene Therapies Advisory Committee discussion of betibeglogene autotemcel (beti-cel) for the treatment of people with beta-thalassemia who require regular red blood cell transfusions.